Reported net revenues of $9.1 million for Q1 2026, down from $11.7 million in Q1 2025. Net loss attributable to common shareholders was $3.3 million for the quarter, compared to a net income of $1.3 million in the prior year period. Announced a strategic transaction to sell its commercial product portfolio, including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, to Apotex for $100 million. Retaining development programs and majority ownership in Cumberland Emerging Technologies (CET) to pivot toward a development-stage biopharmaceutical profile. FDA granted Fast Track Designation for ifetroban for Duchenne muscular dystrophy (DMD) in Q1 2026.